Activator protein 1 (AP-1) transactivation and ornithine decarboxylase (ODC) activity have been established as essential downstream eectors of mouse skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate (TPA). Previous studies have shown that inhibition of either AP-1 transactivation or ODC activity suppressed tumor promoter-induced transformation. By utilizing the JB6 mouse epidermal cell system, the present study determined whether TPA-induced ODC gene expression and activity is independent of AP-1 transactivation. In three independent JB6 (P + ) clones, stably expressing dominant negative c-jun, TPA-induced ODC gene expression and activity were similar compared to JB6 P + cells expressing vector-control alone, while AP-1-dependent transcription was inhibited. Transformationinsensitive JB6 (P 7 ) cells, which lack TPA-inducible cjun expression, also exhibited similar induction of ODC activity by TPA. a-Di¯uoromethylornithine, an irreversible inhibitor of ODC, attenuated, at an equivalent IC 50 , both TPA-induced ODC activity and anchorage-independent growth of JB6 P + cells, despite no inhibition of AP-1 transactivation. Taken together, the results presented indicate that TPA-induced ODC gene expression and activity are independent of AP-1 transactivation. Because inhibition of either AP-1 or ODC precludes TPA-induced transformation, and because ODC is independent of AP-1, we propose that there are at least two pathways to transformation. Each pathway is required but not sucient for transformation.
Introduction
Mouse skin carcinogenesis has provided an excellent model in de®ning the irreversible genetic events of initiation and progression and the epigenetic events of tumor promotion during neoplastic development (Boutwell, 1974; Verma and Boutwell, 1980; Furstenberger et al., 1985; Slaga et al., 1996) . Initiation by carcinogens occurs rapidly, at a high frequency, and is not a rate-limiting event in neoplastic development. Conversely, tumor promotion occurs slowly, at a low frequency and is a rate-limiting event in tumor development (Boutwell, 1974; Verma and Boutwell, 1980; Furstenberger et al., 1985; Slaga et al., 1996) . Because initiation of a cell may be inevitable due to the ubiquity of carcinogens, prevention of cancer may be most eectively achieved by inhibiting the early, reversible promotion stage leading to a benign tumor before its progression to malignancy.
The JB6 mouse epidermal cell system is a useful model for the study of promoter-dependent biochemical events of preneoplastic progression (Colburn et al., 1979 (Colburn et al., , 1981 Bernstein and Colburn, 1989; Cmarik and Colburn, 1997) . JB6 P + transformation-sensitive cells are transformed into neoplastic cells by many tumor promoters including the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) (Colburn et al., 1979) . JB6 P 7 transformation-resistant cells are refractory to TPA-induced neoplastic transformation but not to other TPA-induced responses such as mitogenic stimulation (Colburn et al., 1981) . The JB6 system has been characterized extensively for dierences in susceptibility to neoplastic transformation as well as for molecular responses to tumor promoters (Colburn et al., 1981; Bernstein and Colburn, 1989; Cmarik and Colburn, 1997) .
TPA-induced ornithine decarboxylase (ODC) activity has been shown to be essential for mouse skin tumor promotion by TPA (Gilmour et al., 1987; Verma, 1992; O'Brien et al., 1997) . ODC activity has been shown to have multiple levels of control from transcriptional control (Katz and Kahana, 1987) through posttranslational modi®cations (Lu et al., 1991; Ray et al., 1999) . a-Di¯uoromethylornithine (DFMO), an irreversible inhibitor of ODC activity, inhibits the formation of mouse skin tumors promoted by TPA (Takigawa et al., 1982; Weeks et al., 1982) . ODC is the rate-limiting enzyme in the biosynthesis of mammalian polyamines. Polyamine metabolism plays a decisive role in nucleic acid synthesis, cell proliferation and dierentiation, as well as malignant transformation (Pegg, 1986) . However, TPA-induced events upstream of ODC activation are not well understood.
From studies utilizing reporter constructs measuring AP-1-dependent gene expression, the induction of AP-1 transactivation also has been shown to be essential for tumor promotion and progression in cell culture models (Dong et al., 1994 (Dong et al., , 1997 Li et al., 1998; Domann et al., 1994) . In JB6 and human keratinocyte models, expression of dominant negative c-jun can block induced AP-1 activity and neoplastic transformation (Dong et al., 1994 (Dong et al., , 1997 Li et al., 1998; Domann et al., 1994) . TPA-induced upregulation of the AP-1 transcription factor complex occurs prior to TPAinduced ODC gene expression. However, it is unknown whether ODC is an AP-1 target gene.
In order to determine whether ODC is an AP-1 target gene, the human ODC promoter was cloned and analysed for TPA responsiveness of the consensus AP-1 sequences located in ODC introns 3, 5 and 11 (Tseng and Verma, 1995; Kim et al., 1994) . The AP-1 consensus sequence (TGAGTCA) is a major TPA responsive element shared by several TPA inducible genes, such as hMTIIA, SV40, collagenase, and stromelysin (Angel et al., 1987) . TPA treatment of CV-1 cells transiently transfected with ODC intron reporter constructs showed no increase in reporter gene activity (Tseng and Verma, 1995) . This suggested that the AP-1 sequences in the ODC introns were silent. Reddig et al. (1996) narrowed the region of TPA responsiveness to the sequence 742/+54 relative to the transcriptional start site. This region does not contain an AP-1 consensus sequence. These results led us to suggest that AP-1 does not play a direct or cis role in the induction of ODC by TPA.
The use of partial promoters to determine whether AP-1 is involved in transactivation of ODC gene expression did not rule out the possibility that the fulllength endogenous promoter may be dependent on AP-1 transcription factor activity. TPA-induced ODC activity might still involve AP-1 in an indirect or trans role. AP-1 may induce one or more secondary gene products that may be responsible for ODC induction.
To determine whether ODC gene expression and AP-1 transactivation are events linked on the same pathway or are independent events on dierent pathways of TPA promotion, we chose to utilize the JB6 mouse epidermal system. Dong et al. (1994) previously created stable JB6 cell lines that overexpressed a truncated c-Jun protein, TAM67. The mutant c-Jun protein sequesters endogenous AP-1 factors in a dominant negative manner, inhibiting inducible AP-1 activity and neoplastic transformation (Brown et al., 1993) .
We present data in this communication consistent with the hypothesis that TPA-induced ODC activation occurs independently of AP-1 activation. In JB6 cells overexpressing TAM67, inhibition of AP-1 has no eect on ODC gene expression or activity. Since inhibition of either AP-1 or ODC inhibits TPAinduced transformation and ODC induction occurs independently of AP-1 activation, we propose that TPA-induced upregulation of AP-1 and ODC are not directly linked and occur on two independent pathways. Each pathway is required but not sucient for transformation. Inhibition of either pathway may preclude cellular transformation.
Results
TPA induces ODC and AP-1 transcription factor activity TPA-induced ODC activity was characterized in transformation sensitive JB6 P + cells (Cl 41-5a). Optimal ODC induction was observed after treatment with 10 nM TPA ( Figure 1A) . A time course study revealed induction of ODC up to 24 h with optimal induction occurring 9 h after TPA treatment ( Figure  1B ).
TPA-induced AP-1 activity was assayed in Col-19 cells. The Col-19 cell line was cloned after stable transfection of JB6 P + cells with a 773/+67 collagenase luciferase reporter construct containing one AP-1 consensus sequence (TGAGTCA) (Li et al., 1996) . After culture in low serum (0.25%) for 36 h, the fold-induction of AP-1 activity at 24 h after treatment with 10, 50 or 100 nM TPA was 3.4, 4.4, and 4.5, respectively (Figure 2 ).
Lack of AP-1 induction is not accompanied by lack of ODC induction JB6 P 7 cells (Colburn et al., 1981) have been demonstrated to lack AP-1 inducibility after TPA or epidermal growth factor treatment (Bernstein and Colburn, 1989) . The lack of AP-1 induction appears to contribute to the resistance to TPA-induced transformation based on the following evidence: (1) restoration of AP-1 response by expression of Erk in P 7 cells restored transformation response (Huang et al., 1998) and (2) 
TPA-induced ODC expression and activity are not inhibited by expression of TAM67, a dominant negative c-Jun inhibitor
Previous ®ndings appear to have cast doubt on the direct or cis involvement of AP-1 on upregulation of the ODC gene expression. The TPA-inducible promoter region of ODC has been characterized. The inducible sequence is located 742/+54 relative to the transcriptional start site (Reddig et al., 1996) . However, this region does not contain known AP-1 consensus DNA binding sequences. The AP-1 sequences located in introns 3, 5, and 11 of the ODC gene do not respond to TPA (Tseng and Verma, 1995; Kim et al., 1994) . These ®ndings preclude the role of AP-1 in direct transcriptional activation of ODC gene expression.
Although AP-1 may not be directly involved in cisregulated ODC gene transcription, the AP-1 complex might induce a trans-activated gene involved in ODC upregulation after TPA treatment. If AP-1 induced a gene whose product was responsible for upregulation of ODC, inhibition of AP-1 activity expression should inhibit TPA-induced ODC activity. To test this hypothesis a truncated c-Jun protein, TAM67, was expressed in JB6 P + cells. TAM67 lacks the transcriptional transactivating domain of c-Jun and acts in a dominant negative manner inhibiting AP-1 activity. Three separate JB6 P + clones (1ME, 3MB, 3MC), stably transfected with TAM67, inhibited neither TPAinducible ODC gene expression ( Figure 4B and C) nor ODC enzymatic activity ( Figure 4A ).
Either DFMO treatment or overexpression of dominant negative c-jun mutant inhibits TPA-induced transformation
Expression of TAM67 inhibits TPA-induced transformation. The three separate JB6 P + clones (1ME, 3MB, 3MC), stably transfected with TAM67, also showed inhibited transformation in response to TPA ( Figure  5A ). The overexpression of TAM67 was con®rmed via Western blot ( Figure 5B ). The truncated 29 kDa c-Jun dominant negative protein, TAM67, can be seen migrating faster than the wild type 39 kDa c-Jun protein. TAM67 can be seen as two bands of approximately 29 kDa which is characteristic of TAM67 expression (Dong et al., 1994 (Dong et al., , 1997 Li et al., 1996) . TAM67 expression was not seen in a neo control cell line ( Figure 5B ). The functionality of TAM67 as an AP-1 inhibitor was con®rmed by measuring TPAinduced luciferase activity after transient transfection of a collagenase luciferase reporter construct. TPAinduced AP-1 activity was inhibited in TAM67 overexpressing clones as compared to a neo control cell line ( Figure 5C ).
TPA is a potent phorbol ester shown to promote mouse skin tumor formation. DFMO, an irreversible inhibitor of ODC, can prevent tumor promotion by TPA and regress already established mouse skin papillomas (Takigawa et al., 1982; Verma, 1992) . Anchorage-independent growth is a characteristic of cellular transformation. JB6 P + cells are a good model for studying TPA-induced transformation because JB6 P + cells transform consistently with a single treatment of TPA. In JB6 P + cells, anchorage-independent transformation was attenuated by DFMO. One mM DFMO completely inhibited transformation by 10 nM TPA ( Figure 6B ). The IC 50 (1 mM) for DFMO inhibition of ODC activity ( Figure 6A ) and JB6 transformation ( Figure 6B ) was similar. The attenuation of ODC activity by DFMO showed the same IC 50 as that for inhibition of transformation.
DFMO inhibition of ODC activity does not inhibit AP-1 activity
If TPA-induced ODC activity and AP-1 transactivation are due to activation of separate pathways, . Serum-starved Col-19 cells were harvested 24 h after treatment with the indicated dose of TPA. Cell lysates were assayed for luciferase activity to determine AP-1 dependent transactivation. Each value is the mean+s.d. of three experiments Figure 3 TPA induces ODC activity in JB6 P 7 cells to similar levels as JB6 P + cells. Serum-starved cells were harvested after TPA (10 nM) treatment at the indicated time points to assay for ODC activity. Each value is the mean+s.e.m. of three experiments inhibition of ODC should have no eect on AP-1 activity. To rule out the possibility that TPA-induced ODC activity occurs upstream of the formation of the AP-1 transactivating complex, the AP-1 reporter Col-19 cells were pretreated with 1 mM DFMO for 12 h after an initial 24 h of 0.25% serum starvation. Upon treatment with 50 nM TPA, the Col-19 cells responded with nearly equal AP-1-induced luciferase activity whether with or without DFMO pretreatment ( Figure 7A ). ODC activity was abolished by the DFMO pretreatment ( Figure 7B ). Neither ODC activity nor AP-1 transactivation appears to be dependent on one another.
Discussion
Many TPA-inducible genes appear to be dependent on at least one AP-1 consensus sequence (TGAGTCA) within the promoter region for full induction of gene expression (Angel et al., 1987) . This has been consistently seen with reporter constructs driven by segments of gene promoters containing AP-1 sequences. However, AP-1 dependent transformation has not yet been directly attributed to speci®c endogenous target genes. Despite the inducibility of ODC gene expression by TPA and the necessity for ODC activity in TPA-induced transformation, the Northern blot analysis for steady state ODC mRNA was done using a randomly primed 32 P-labeled ODC cDNA probe (pODC10/2H). 18S RNA was used as the internal control for normalization. (C) Quanti®cation of the autoradiogram of the Northern blot analysis ( Figure 5B ) was done using a phosphoimager. The results are representative of two independent experiments Two mg collagenase luciferase reporter was cotransfected with 0.2 mg pRL-Tk. After 36 h of culture in serum reduced media, serum starved cells were harvested 20 h after treatment with the indicated dose of TPA. Cell lysates were analysed for AP-1-dependent luciferase expression. The fold AP-1 activity was calculated from the triplicate plate average of TPA-induced luciferase activity divided by the triplicate plate average of vehicle control AP-1 activity present results indicate that ODC is not an AP-1 target gene. This conclusion was supported by the following evidence: (1) the ODC promoter contains no AP-1 sites, and (2) neither TPA-induced ODC mRNA levels nor ODC activity is in¯uenced by inhibition of AP-1 activity.
AP-1 consensus sequences are located in introns 3, 5, and 11 of the ODC gene. These sequences do not respond to TPA when subcloned individually into reporter constructs (Tseng and Verma, 1995; Kim et al., 1994) . The sequence in the ODC promoter that does respond to TPA is located 742/+54 relative to the transcriptional start site (Reddig et al., 1996) . However, there is no consensus AP-1 sequence in this region. The above reports suggested the improbability of direct transactivation of ODC gene transcription by the AP-1 transcription factor. The present results corroborate this conclusion. More evidence has also indicated that ODC regulation, at least in part, is at the level of transcription mediated by non-AP-1 sequences (Kim et al., 1994; Katz and Kahana, 1987) .
Despite the lack of evidence that AP-1 is involved in the cis-regulation of ODC activity, AP-1 and ODC may still be on the same pathway downstream of TPA. AP-1 might induce ODC expression and activity by an unknown trans-regulated or indirect mechanism. One or more genes transactivated by AP-1 may be responsible for ODC activity. JB6 cells that were stably expressing a dominant negative mutant of c-jun, TAM67, were characterized for TPA-induced ODC activity. Neither ODC expression nor activity was inhibited by blocking AP-1 activity with TAM67. AP-1 does not trans-activate a secondary gene product that is responsible for TPA-induced ODC activity. The present results suggest that there is no indirect regulation of ODC gene expression by an AP-1 dependent process. The pathway by which TPA transduces its signal for upregulation of ODC gene expression and subsequent enzymatic activity remains to be de®ned.
Although inhibition of AP-1 has no eect on the inducibility of the ODC gene, inhibition of either ODC by the irreversible inhibitor, DFMO, or inhibition of AP-1 by TAM67, inhibits TPA-induced transformation as measured by anchorage-independent colony growth. The IC 50 for DFMO inhibition of transformation was equivalent to the IC 50 for inhibition of ODC activity. JB6 transformation-insensitive P 7 cells lack inducible AP-1 activity which is attributed to a de®ciency in extracellular signal-regulated kinase (Erk) activity (Huang et al., 1998) . However JB6 P 7 cells induce ODC activity to similar levels as JB6 P + cells. ODC is induced in cells de®cient in the ERK pathway. This suggests that there are possibly two independent pathways for cellular transformation. The ODC induction response and the AP-1 activation response to TPA occur on independent pathways and inhibition of either pathway can inhibit transformation. One possible explanation for the DFMO inhibition of transformation is that ODC is acting upstream of AP-1. This is not the case since DFMO, at a dose that completely inhibits transformation and ODC activity, has no eect on the fold-induction of AP-1 compared to cells without DFMO.
Since evidence suggests that ODC induction is independent of AP-1-dependent pathways, a critical question remains to be answered. What is the ODC pathway necessary for transformation? ODC is believed to be a transcriptional target of another immediate early gene, c-myc (Bello-Fernandez et al., 1993; Wagner et al., 1993) . There is a c-Myc-Max binding site (CACGTG) in ODC intron 1 shown to be involved in c-Myc induction of an ODC promoterreporter gene construct (Bello-Fernandez et al., 1993) . Overexpressed c-Myc has been shown to activate ODC gene expression independent of growth factors (BelloFernandez et al., 1993) . However, Bush et al. (1998) reported no dierence in serum-induced ODC gene expression in ®broblasts that had c-myc knocked out compared to wild type ®broblasts when normalized to GADPH levels. Packham and Cleveland (1997) have postulated a biphasic model in which ODC gene expression is regulated by two independent pathways after interleukin-3 (IL-3) stimulation. The initial cytokine-induced ODC gene expression is c-Mycindependent. ODC gene expression becomes c-Mycdependent only at a later time point after IL-3 stimulation in murine myeloid cells (Packham and Cleveland, 1997 ).
TPA's major receptor is protein kinase C (Driedger and Blumberg, 1980; Niedel et al., 1983; Ashendel et al., 1983; Kikkawa et al., 1983) . Both ODC and AP-1 are downstream of PKC. The two-pathway model of transformation we propose must bifurcate downstream of PKC activation. Our model is consistent with Packham and Cleveland's model of c-Myc-dependent ODC expression (Bello-Fernandez et al., 1993) . The mechanism of initial induction of ODC that is independent of c-Myc remains unclear. Potentially the early induction of ODC may rely on upregulation of basal transcriptional machinery.
The dominant negative c-Jun (TAM67) used in these experiments has also been shown to trans-repress NFkB-dependent transactivation (Dong et al., 1997; Li et al., 1998 ). An HIV-NF-kB collagenase reporter construct was used to show inhibited NF-kB-dependent transcription when co-transfected with TAM67 in mouse keratinocytes or HPV immortalized human keratinocytes (Dong et al., 1997; Li et al., 1998) . The NF-kB/Rel transcription factor family has been shown to regulate c-Myc gene transcription in immature B lymphocytes (Lee et al., 1995) . However, inhibition of NF-kB may not preclude the role of other factors in the positive regulation of c-Myc gene expression in mouse epidermal cells.
How might ODC and AP-1 complement or synergize to traverse the rate-limiting stage of tumor promotion in neoplastic development? There is evidence that ODC induction is required for the proliferative stimulus or hyperplasia that is necessary but not sucient for tumor promotion (Hsieh et al., 1990) . There is also evidence that AP-1 induction is not necessary for proliferative stimulus or hyperplasia. JB6 P 7 transformation-insensitive cells are still mitogenically responsive, and TAM67 expression in other cell lines also did not inhibit growth yet blocked transformation (Dong et al., 1994 (Dong et al., , 1997 Li et al., 1998) . Transgenic mice overexpressing TAM67 in the skin show AP-1 inhibition, but hyperplasia still occurs following TPA treatments (Young et al, submitted) . The tumor promotion relevant AP-1 target genes, which make AP-1 transactivation necessary for cellular transformation, remain to be de®ned.
Inhibition of tumor promotion and subsequent progression is more feasible as a goal for prevention of cancer and inhibition of carcinogenesis than blocking initiation. Both ODC (Love et al., 1998; Carbone et al., 1998) and AP-1 (Fanjul et al., 1994) have been chosen as potential targets for chemoprevention in clinical trials. The understanding of how two important chemoprevention targets, ODC and AP-1, interact with each other is important in the possible future understanding and development of strategies for rational prevention of cancer. 
Materials and methods

Materials
Cell lines
JB6 P
+ (Cl 41-5a) and JB6 P 7 (Cl 30-7b) were purchased from ATCC (Rockville, MD, USA). JB6 Col-19 AP-1-Luciferase (24), JB6pmmTAM67 (15), and JB6neo (15) cell clones were provided by Dr NH Colburn. All JB6 parental cells and clones were cultured in MEM supplemented with 5% FBS, 100 U/ml penicillin, and 100 mg/ml streptomycin. JB6 Col-19, JB6 TAM67, and JB6neo clones were additionally selected in 500 mg/ml, 400 mg/ml, and 400 mg/ ml geneticin, respectively.
ODC activity assay
At 50 ± 70% con¯uency, cells were serum starved for 24 ± 48 h in 0.25 or 2% FBS supplemented MEM and then were treated. DFMO was dissolved in double distilled water. Cells were harvested in buer containing 50 mM Tris-HCl (pH 7.5), 0.1 mM pyridoxal-5-phosphate, 0.1 mM EDTA, and 1 mM DTT. ODC activity in the soluble extract was determined by measuring the release of 14 CO 2 from dl-[1-14 C]ornithine hydrochloride. The protein concentration in soluble extracts was determined with Bio-Rad Protein Assay (Hercules, CA, USA).
Transfection and luciferase assay for AP-1-dependent transcriptional activity Transient transfections were performed in 6-well plates with LipofectAMINE enhanced cellular plasmid uptake (Gibco ± BRL). In TAM67 stable transfectants, 2 mg collagenase luciferase reporter plasmid was cotransfected with 0.25 mg of the constitutive reporter vector, pRL-TK in OPTI-MEM-1. After incubation in transfection media for 5 h, the media was aspirated and the cells were allowed to recover for 12 ± 15 h in 5% FBS MEM. The cells were then serum starved in 0.25% FBS MEM for 24 h and then treated with 10 nM TPA or 0.1% ethanol for another 24 h. Cells were harvested in Promega Passive Lysis Buer. The ®re¯y luciferase of the collagenase luciferase reporter construct and the Renilla luciferase activity of the constitutive pRL-TK were assayed by using substrates provided in the Dual-Luciferase Reporter Assay System (Promega). The bioluminescent signal was measured with a Monolight 2010 Luminometer (Analytical Luminescence Laboratory, San Diego, CA, USA). Induced ®re¯y luciferase activity was normalized to constitutive Renilla luciferase activity.
JB6 P + cells were previously stably transfected with a 773/+63 collagenase luciferase reporter gene (Col-19) (15). Lysate was collected from cells serum starved for 36 h in 0.25% FBS MEM and then treated with either the indicated dose of TPA or ethanol for 24 h. Luciferase activity was assayed with substrate provided by Promega and normalized to the lysate's protein concentration.
Anchorage-independent transformation assay
Cells were suspended in 0.33% agarose medium containing solvent alone (0.1%) or TPA (10 nM) and layered at 10 4 cells per 60-mm dish over a 0.5% agar base. Colonies with at least 25 cells were counted after 14 days.
Immunoprecipitation analysis of c-Jun and TAM67
Tam67 or vector-only JB6 stable transfectants were metabolically labeled with 35 S-methionine (0.2 mCi/ml). Polyclonal rabbit anti-c-Jun, Ab-1 (Oncogene Science, Uniondale, NY, USA) was used to precipitate the protein of interest from cell lysates prepared as described previously. Immunoprecipitate was fractionated by electrophoresis through a 12.5% SDS-polyacrylamide gel. The protein was detected by autoradiography.
Northern blot analysis
Total RNA was extracted with Trizol reagent as described by the manufacturer. 12.5 mg of total RNA was fractionated on a denaturing formaldehyde-agarose gel. The RNA was transferred to GeneScreen using Stratagene's Posiblot 30-30 Pressure Blotter (La Jolla, CA, USA) and UV crosslinked. pODC10/2H or 18S cDNA fragments were labeled with a-32 P-dCTP with Boehringer Mannheim's Random Primed DNA Labeling Kit (Indianapolis, IN, USA) and used as probes for ODC and 18S RNA. Signals were visualized by autoradiography and quantitated by a PhosphoImager with ImageQuant (Molecular Dynamics, Sunnyvale, CA, USA).
Abbreviations TPA, 12-O-tetradecanoylphorbol-13-acetate; DFMO, adi¯uoromethylornithine; ODC, ornithine decarboxylase; PKC, protein kinase C.
